Cardiff Oncology, Inc.CRDFNASDAQ
Loading
EV to Sales: Premium ValuationElevated
Percentile Rank79
3Y CAGR+33.0%
5Y CAGR-15.5%
Year-over-Year Change
Enterprise value to sales ratio
3Y CAGR
+33.0%/yr
Annual compound
5Y CAGR
-15.5%/yr
Recent acceleration
Percentile
P79
Within normal range
vs 5Y Ago
0.4x
Contraction
Streak
2 yr
Consecutive growthElevated
| Period | Value | YoY Change |
|---|---|---|
| 2025 | 288.68 | +25.7% |
| 2024 | 229.65 | +140.4% |
| 2023 | 95.52 | -22.2% |
| 2022 | 122.82 | -80.5% |
| 2021 | 628.82 | -6.2% |
| 2020 | 670.57 | +15556.7% |
| 2019 | -4.34 | +59.4% |
| 2018 | -10.70 | -240.1% |
| 2017 | 7.64 | -93.1% |
| 2016 | 110.26 | - |